Active Biotech AB (ACTI.ST)
25 Nov 2014
|Market Cap (Mil.):||kr1,768.20|
|Shares Outstanding (Mil.):||74.92|
STOCKHOLM, Nov 5 - Active Biotech Ab, July-September:
* Teva and Active Biotech announce expansion of Laquinimod clinical development program with new trial in primary progressive multiple sclerosis and first patient screened in Huntington's Disease trial Source text for Eikon: Further company coverage:
Earnings vs. Estimates
Analyst Research Reports
Active Biotech AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.